[go: up one dir, main page]

MX2022013840A - Polipéptidos de unión a pd-1 canina y usos de los mismos. - Google Patents

Polipéptidos de unión a pd-1 canina y usos de los mismos.

Info

Publication number
MX2022013840A
MX2022013840A MX2022013840A MX2022013840A MX2022013840A MX 2022013840 A MX2022013840 A MX 2022013840A MX 2022013840 A MX2022013840 A MX 2022013840A MX 2022013840 A MX2022013840 A MX 2022013840A MX 2022013840 A MX2022013840 A MX 2022013840A
Authority
MX
Mexico
Prior art keywords
canine
binding polypeptides
vhh
containing polypeptides
bind
Prior art date
Application number
MX2022013840A
Other languages
English (en)
Inventor
Rajay Pandit
Brendan P Eckelman
John C Timmer
Quinn Deveraux
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of MX2022013840A publication Critical patent/MX2022013840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se proporcionan polipéptidos que contienen VHH que se unen a la PD-1 canina; en algunas modalidades, se proporcionan polipéptidos que contienen VHH que se unen y antagonizan la PD-1 canina; también se proporcionan usos de los polipéptidos que contienen VHH.
MX2022013840A 2020-05-04 2021-05-03 Polipéptidos de unión a pd-1 canina y usos de los mismos. MX2022013840A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019817P 2020-05-04 2020-05-04
PCT/US2021/030476 WO2021225961A1 (en) 2020-05-04 2021-05-03 Canine pd-1-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2022013840A true MX2022013840A (es) 2023-02-09

Family

ID=76076497

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013840A MX2022013840A (es) 2020-05-04 2021-05-03 Polipéptidos de unión a pd-1 canina y usos de los mismos.

Country Status (10)

Country Link
US (1) US20230331846A1 (es)
EP (1) EP4146696A1 (es)
JP (1) JP2023524995A (es)
KR (1) KR20230005955A (es)
CN (1) CN115776990A (es)
AU (1) AU2021266688A1 (es)
BR (1) BR112022022352A2 (es)
CA (1) CA3177921A1 (es)
MX (1) MX2022013840A (es)
WO (1) WO2021225961A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110982824B (zh) * 2019-10-09 2022-04-15 天津大学 拮抗pd-1的抗体类似物bp基因及蛋白和应用
EP4652197A1 (en) * 2023-01-20 2025-11-26 Petmedix Ltd. Therapeutic antibodies
CN117343185B (zh) * 2023-12-06 2024-03-01 北京伟杰信生物科技有限公司 一种抗犬pd-1抗体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
BR112014010008A2 (pt) * 2011-10-26 2018-09-04 Novartis Ag anticorpos monoclonais, seus usos e ácidos nucleicos
EP4566623A3 (en) * 2013-12-20 2025-08-20 Intervet International B.V. Caninized antibodies
WO2016006241A1 (ja) * 2014-07-09 2016-01-14 日本全薬工業株式会社 抗イヌｐｄ－１抗体又は抗イヌｐｄ－ｌ１抗体
PL3177644T3 (pl) * 2014-08-05 2021-06-14 MabQuest SA Immunologiczne reagenty wiążące do PD-1
EP3201230B1 (en) * 2014-09-30 2020-12-23 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
EP3864049A1 (en) * 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CN113087797B (zh) * 2019-06-03 2021-12-31 北京希诺谷生物科技有限公司 抗犬pd-1抗体及其应用

Also Published As

Publication number Publication date
US20230331846A1 (en) 2023-10-19
BR112022022352A2 (pt) 2023-01-10
EP4146696A1 (en) 2023-03-15
CN115776990A (zh) 2023-03-10
KR20230005955A (ko) 2023-01-10
AU2021266688A1 (en) 2022-12-08
WO2021225961A1 (en) 2021-11-11
JP2023524995A (ja) 2023-06-14
CA3177921A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2022013840A (es) Polipéptidos de unión a pd-1 canina y usos de los mismos.
PH12019550147A1 (en) Engineered transferrin receptor binding polypeptides
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
WO2019183359A8 (en) Methods and compositions for molecular authentication
PH12020551716A1 (en) Anti-ror antibody constructs
WO2020160156A3 (en) Anti-gal3 antibodies and uses thereof
MX2019007020A (es) Anticuerpos il-11.
JOP20170017B1 (ar) تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
WO2020127377A9 (en) Bifunctional anti-pd-1/il-7 molecule
ZA202106602B (en) Claudin 6 antibodies and uses thereof
PH12021552970A1 (en) Tigit and pd-1/tigit-binding molecules.
MX2021013416A (es) Polipeptidos de union al antigeno cd33 y sus usos.
PH12020550556A1 (en) Novel combinations of defoliants
WO2020169809A3 (de) Verfahren zur geruchsreduktion partikelförmiger kohlenstoffmaterialien
CR20230531A (es) Composiciones de anticuerpos anti-tslp y usos de las mismas
MX2021003159A (es) Microemulsiones que contienen antioxidantes.
PH12020550217A1 (en) Nutrient-spore formulations and uses thereof
EP4588524A3 (en) Anti-tigit and anti-pvrig in monotherapy and combination treatments
MX2022011077A (es) Variantes de transglutaminasa.
MX2020013742A (es) Composición aglutinante de concreto diseñado que comprende componente mecano-químicamente modificado y su método de producción.
SG10201806051XA (en) Compositions containing polymeric carbodiimide, epoxide and polyester-based polymers, their production and use
WO2023014908A8 (en) Lpar1 antagonists and uses thereof
WO2023091195A3 (en) Group14 composite
MX2024003331A (es) Moleculas de union a d3 y usos de estas.